KRAS-Mutant non-small cell lung cancer: From biology to therapy
| Autor: | Luis Paz-Ares, Irene Ferrer, Gerald Schmid-Bindert, Stephan Herbertz, William J. John, Jon Zugazagoitia |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Cancer Research Lung Neoplasms medicine.medical_treatment Drug Resistance Viral Oncogene Synthetic lethality medicine.disease_cause Proto-Oncogene Proteins p21(ras) 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Molecular Targeted Therapy Allele Lung cancer neoplasms Mutation Oncogene business.industry Immunotherapy medicine.disease digestive system diseases respiratory tract diseases Treatment Outcome 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer research KRAS business |
| Zdroj: | Lung Cancer. 124:53-64 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/j.lungcan.2018.07.013 |
| Popis: | In patients with non-small cell lung cancer (NSCLC), the most frequent oncogene driver mutation in Western countries is Kirsten rat sarcoma viral oncogene homolog (KRAS), and KRAS-mutant NSCLC is associated with smoking. There are various sources of biological heterogeneity of KRAS-mutant NSCLC, including different genotypes that may be associated with specific clinical outcomes, the presence of other co-mutations that exhibit different biological features and drug sensitivity patterns, and mutant allelic content. The efficacy of chemotherapy in patients with KRAS-mutant NSCLC is generally poor and numerous novel therapeutic strategies have been developed. These approaches include targeting KRAS membrane associations, targeting downstream signalling pathways, the use of KRAS synthetic lethality, direct targeting of KRAS, and immunotherapy. Of these, immunotherapy may be one of the most promising treatment approaches for patients with KRAS-mutant NSCLC. Recent data also suggest the potential for distinct efficacy of immunotherapy according to the presence of other co-mutations. In view of the biological heterogeneity of KRAS-mutant NSCLC, treatment will likely need to be individualised and, in future, may require the use of rational combinations of treatment, many of which are currently under investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect